Meeting
2019 Genitourinary Cancers Symposium
Analysis of real-world PD-L1 testing in patients with urothelial carcinoma.
Authors
Gabriel S Krigsfeld
Bristol-Myers Squibb, Princeton, NJ
Gabriel S Krigsfeld , Emily Prince , Kim Zerba , Vladislav Chizhevsky , Josette William Ragheb , James Novotny Jr., James William White
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 447)
DOI
10.1200/JCO.2019.37.7_suppl.447
Abstract #
447
Poster Bd #
J18
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Discordance rate of PD-L1 expression between primary and metastatic lesions in urothelial carcinoma (UC).
First Author: Earle Frederick Burgess
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Microsatellite instability (MSI) in patients with gastric cancer (GC) and correlation with PD-L1 expression.
First Author: Henian Sun
Poster
2020 ASCO Virtual Scientific Program
Molecular correlates of response to preoperative olaparib alone or with cisplatin or with durvalumab in head and neck squamous cell carcinoma (HNSCC): A Hellenic Cooperative Oncology Group study.
First Author: Amanda Psyrri
Poster
2018 ASCO Annual Meeting
Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy.
First Author: Magda Zajac